Scott W. Lowe

Scott W. Lowe is a Professor and Chair of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center (MSKCC), and an Investigator at the Howard Hughes Medical Institute. His research focuses on the genetic mechanisms of cancer, particularly the role of tumor suppressor genes like p53 in tumorigenesis, therapy response, and cellular senescence.

His research interests include:

• Cancer genetics and evolution
• Cellular senescence in tumor suppression and aging
• Functional and cancer genomics
• Mouse modeling of cancer
• Immune interactions in cancer therapy
• Therapeutic strategies targeting senescent cells

Dr. Lowe's work has revealed fundamental insights into how p53 regulates cell metabolism, genome stability, and cell fate decisions in cancer. His lab integrates sophisticated genetic tools, genomic approaches, and single-cell analyses to identify cancer drivers and therapeutic vulnerabilities.

His scientific honors include:

• Howard Hughes Medical Institute Investigator
• Member of the National Academy of Sciences
• Member of the National Academy of Medicine
• Member of the American Academy of Arts and Sciences
• Fellow of the American Association for Cancer Research
• Outstanding Investigator Award and G.H.A. Clowes Award (AACR)
• Paul Marks Prize
• Alfred G. Knudsen Award (NIH)

Dr. Lowe has led major research initiatives in cancer biology and has trained numerous scientists through his leadership at MSKCC and Cold Spring Harbor Laboratory. His lab continues to pioneer new methods such as the MACHETE technique for studying copy number alterations in cancer. He has secured significant research funding through HHMI and institutional support, enabling long-term, high-impact research. His work bridges basic science and translational applications, with implications for both cancer treatment and aging-related diseases.

He leads the Cancer Biology and Genetics Program at the Sloan Kettering Institute, fostering interdisciplinary collaboration and innovation in cancer research. His team utilizes cutting-edge technologies to accelerate cancer discovery and develop novel therapeutic strategies.